Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Contemporary Oncology (Poznan, Poland)|February 26, 2024
Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective studyPiotr Domański, Jadwiga Jarosińska, Barbara Kruczyk, et al.Contemporary Oncology (Poznan, Poland)|January 19, 2024
Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective studyPiotr Domański, Jadwiga Jarosińska, Barbara Kruczyk, et al.Biomedicines|February 24, 2024
Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective StudyPiotr Domański, Mateusz Piętak, Barbara Kruczyk, et al.Central European Journal of Urology|January 28, 2017
Primary penile cancer organ sparing treatmentRoman Sosnowski, Marcin Kuligowski, Olga Kuczkiewicz, et al.Medicina (Kaunas, Lithuania)|March 28, 2024
Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative ReviewPiotr Domański, Mateusz Piętak, Szymon Staneta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinomaBernard Escudier, Cezary Szczylik, Thomas E Hutson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.Medical Oncology (Northwood, London, England)|August 9, 2020
What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical interventionGrazyna Poniatowska, Wojciech Michalski, Jakub Kucharz, et al.The Oncologist|May 18, 2021
Succinate Dehydrogenase-Deficient Renal Cancer Featuring Fructose-1,6-Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case ReportMichal Szymanski, Natalia Rusetska, Iga Jancewicz, et al.International Journal of Cancer|June 9, 2004
Increased cancer risk of heterozygotes with NBS1 germline mutations in PolandJan Steffen, Raymonda Varon, Maria Mosor, et al.Pageof 6